Calmodulinopathy in Japanese Children - Their Cardiac Phenotypes Are Severe and Show Early Onset in Fetal Life and Infancy.


Journal

Circulation journal : official journal of the Japanese Circulation Society
ISSN: 1347-4820
Titre abrégé: Circ J
Pays: Japan
ID NLM: 101137683

Informations de publication

Date de publication:
24 11 2023
Historique:
medline: 28 11 2023
pubmed: 29 6 2023
entrez: 28 6 2023
Statut: ppublish

Résumé

Cardiac calmodulinopathy, characterized by a life-threatening arrhythmia and sudden death in the young, is extremely rare and caused by genes encoding calmodulin, namely calmodulin 1 (CALM1), CALM2, and CALM3.Methods and Results: We screened 195 symptomatic children (age 0-12 years) who were suspected of inherited arrhythmias for 48 candidate genes, using a next-generation sequencer. Ten probands were identified as carrying variants in any of CALM1-3 (5%; median age 5 years), who were initially diagnosed with long QT syndrome (LQTS; n=5), catecholaminergic polymorphic ventricular tachycardia (CPVT; n=3), and overlap syndrome (n=2). Two probands harbored a CALM1 variant and 8 probands harbored 6 CALM2 variants. There were 4 clinical phenotypes: (1) documented lethal arrhythmic events (LAEs): 4 carriers of N98S in CALM1 or CALM2; (2) suspected LAEs: CALM2 p.D96G and D132G carriers experienced syncope and transient cardiopulmonary arrest under emotional stimulation; (3) critical cardiac complication: CALM2 p.D96V and p.E141K carriers showed severe cardiac dysfunction with QTc prolongation; and (4) neurological and developmental disorders: 2 carriers of CALM2 p.E46K showed cardiac phenotypes of CPVT. Beta-blocker therapy was effective in all cases except cardiac dysfunction, especially in combination with flecainide (CPVT-like phenotype) and mexiletine (LQTS-like). Calmodulinopathy patients presented severe cardiac features, and their onset of LAEs was earlier in life, requiring diagnosis and treatment at the earliest age possible.

Sections du résumé

BACKGROUND
Cardiac calmodulinopathy, characterized by a life-threatening arrhythmia and sudden death in the young, is extremely rare and caused by genes encoding calmodulin, namely calmodulin 1 (CALM1), CALM2, and CALM3.Methods and Results: We screened 195 symptomatic children (age 0-12 years) who were suspected of inherited arrhythmias for 48 candidate genes, using a next-generation sequencer. Ten probands were identified as carrying variants in any of CALM1-3 (5%; median age 5 years), who were initially diagnosed with long QT syndrome (LQTS; n=5), catecholaminergic polymorphic ventricular tachycardia (CPVT; n=3), and overlap syndrome (n=2). Two probands harbored a CALM1 variant and 8 probands harbored 6 CALM2 variants. There were 4 clinical phenotypes: (1) documented lethal arrhythmic events (LAEs): 4 carriers of N98S in CALM1 or CALM2; (2) suspected LAEs: CALM2 p.D96G and D132G carriers experienced syncope and transient cardiopulmonary arrest under emotional stimulation; (3) critical cardiac complication: CALM2 p.D96V and p.E141K carriers showed severe cardiac dysfunction with QTc prolongation; and (4) neurological and developmental disorders: 2 carriers of CALM2 p.E46K showed cardiac phenotypes of CPVT. Beta-blocker therapy was effective in all cases except cardiac dysfunction, especially in combination with flecainide (CPVT-like phenotype) and mexiletine (LQTS-like).
CONCLUSIONS
Calmodulinopathy patients presented severe cardiac features, and their onset of LAEs was earlier in life, requiring diagnosis and treatment at the earliest age possible.

Identifiants

pubmed: 37380439
doi: 10.1253/circj.CJ-23-0195
doi:

Substances chimiques

Calmodulin 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1828-1835

Auteurs

Megumi Fukuyama (M)

Department of Cardiovascular Medicine, Shiga University of Medical Science.

Minoru Horie (M)

Department of Cardiovascular Medicine, Shiga University of Medical Science.

Koichi Kato (K)

Department of Cardiovascular Medicine, Shiga University of Medical Science.

Hisaaki Aoki (H)

Department of Pediatric Cardiology, Osaka Women's and Children's Hospital.

Shuhei Fujita (S)

Department of Pediatrics, Toyama Prefectural Central Hospital.

Yoko Yoshida (Y)

Division of Pediatric Electrophysiology, Osaka City General Hospital.

Hisanori Sakazaki (H)

Department of Pediatric Cardiology, Hyogo Prefectural Amagasaki Hospital.

Takako Toda (T)

Department of Pediatrics, University of Yamanashi, Faculty of Medicine.
Department of Pediatric Cardiology, National Cerebral and Cardiovascular Center.

Michihiko Ueno (M)

Department of Pediatrics, Teine Keijinkai Hospital.

Gaku Izumi (G)

Department of Pediatrics, Faculty of Medicine and Graduate School of Medicine, Hokkaido University.

Nobuo Momoi (N)

Department of Pediatrics, Fukushima Medical University School of Medicine.

Jun Muneuchi (J)

Division of Pediatric Cardiology, Department of Pediatrics, Kyushu Hospital, Japan Community Healthcare Organization.

Takeru Makiyama (T)

Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine.

Yoshihisa Nakagawa (Y)

Department of Cardiovascular Medicine, Shiga University of Medical Science.

Seiko Ohno (S)

Department of Bioscience and Genetics, National Cerebral and Cardiovascular Center.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH